Phase 1Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
- Sponsor
- MOMA Therapeutics (Industry)
- Enrollment
- 220 planned
- Conditions
- Advanced Solid Tumor; Metastatic Solid Tumor; Prostate Cancer; Pancreas Cancer; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency
- Interventions
- MOMA-313; Olaparib
- Ages
- adults, older adults
- Registry
- NCT06545942
Full record on ClinicalTrials.gov
From the registry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Primary outcomes
- Number of participants with AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), and/or AEs leading to discontinuation
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered